Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial

BACKGROUND: PB-201, a partial, pancreas/liver-dual glucokinase activator, showed good tolerance and glycaemic effects in multinational studies. This study determined its optimal dose, safety, pharmacokinetics, and pharmacodynamics in Chinese patients with type 2 diabetes. METHODS: In this double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dongyang, Du, Ying, Yao, Xueting, Wei, Yudong, Zhu, Jixiang, Cui, Cheng, Zhou, Hong, Xu, Min, Li, Haiyan, Ji, Linong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585621/
https://www.ncbi.nlm.nih.gov/pubmed/34805810
http://dx.doi.org/10.1016/j.eclinm.2021.101185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8585621/
https://www.ncbi.nlm.nih.gov/pubmed/34805810
http://dx.doi.org/10.1016/j.eclinm.2021.101185

Ejemplares similares